Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$1.13 USD
+0.17 (17.71%)
Updated May 2, 2024 04:00 PM ET
After-Market: $1.02 -0.11 (-9.73%) 5:28 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APVO 1.13 +0.17(17.71%)
Will APVO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for APVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APVO
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
APVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
Illumina (ILMN) Q1 Earnings and Revenues Beat Estimates
Other News for APVO
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Thursday's After-Market Session
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering